 |
|
Ten Things You Need to Know
About Vesicant Extravasations
 CNE worth 1 credit
Release Date:
Expiration Date:
|
April 15, 2008
April 15, 2010 |
|
 |
|
|
| |
Instructions for Participation in Online Activity
1. Read the following information below before beginning the online education article.
2. Study the online education article.
3. Complete the evaluation form and Post-Test
4. Upon successful completion of the online education article you will receive your
Continuing Nursing Education certificate.
Overview and Purpose
The purpose of this activity is to inform nurses of evidence-based prevention, detection, and management of vesicant extravasations so that they can incorporate this information in clinical practice. This activity will enrich the oncology nurse’s contribution to healthcare by providing the nurse with advanced information about vesicant extravasation.
About the Author
Target Audience
This article is intended for staff oncology nurses, supervisors, and research nurses involved in the care of patients with cancer. The level of RN Learner for this activity is intermediate to advanced. 
Learning Objectives
At the conclusion of this online continuing nursing educational activity, the participant will be able to:
1. Identify three (3) causes of vesicant extravasation from implanted ports.
2. Describe the role of the patient in vesicant extravasation prevention, detection, and management.
3. List the signs and symptoms of a vesicant extravasation.
4. Review institutional policies for managing vesicant extravsastions and update as
needed to include Food and Drug Administration (FDA) approved antidotes and treatments
.
Accreditation and Credit Designation
Creative Cancer Concepts is an approved provider of continuing nursing education by the Texas Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
This activity meets Type I criteria for mandatory continuing education requirements toward relicensure as established by the Texas Board of Nursing.
In order to receive continuing nursing education credit for this educational activity, you must successfully complete a post-test (score of 70% or higher) and submit a completed evaluation form.
Disclosure Policy
This educational activity is supported by an educational grant from TopoTarget.
The presenter has disclosed the following companies and the nature of the relationship below:
|
|
|
| |
Employee or Consultant: |
Consultant, TopoTarget USA |
| |
Grant/Research Support: |
None |
| |
Speaker's Bureau: |
None |
| |
Major Stock or Investment Holder: |
None |
| |
Honorarium |
Advogent (medical education company), which received funding from Baxter |
The content and/or presentation of the information Creative Cancer Concepts is providing with this educational offering will promote quality or improvements in healthcare and not a specific proprietary business interest of an entity producing healthcare goods or services consumed by, or used on patients. Creative Cancer Concepts is presenting research funded by a commercial company. The information presented will be based on generally accepted scientific principles and methods, and will not promote the commercial interest of the funding company. If Creative Cancer Concepts is discussing any product use that is off label, Creative Cancer concepts will disclose that the use or indication in question is not currently approved by the FDA for labeling or advertising. 
Commercial Support
Research conducted by commercial companies are designed and presented with scientific objectivity. Learners are informed of any or possible off-label use of a commercial product that is referenced in this activity. Commercial support did not influence the planning or presentation of this activity. Commercial products are distinguished as separate from the activity.
Disclaimer
The material in this program was compiled by Creative Cancer Concepts, Inc. with an educational grant from TopoTarget. This information should not be used by clinicians in the management of patients without evaluation of the patients' condition, possible contraindications, review of the manufacturer's product information, and consultation with recommendations of other authorities.
Copyright ©2008 Creative Cancer Concepts, Inc. All rights reserved.
Privacy Policy
Creative Cancer Concepts, Inc. makes reasonable efforts to ensure that privacy issues are handled responsibly. CCC does not sell or share your information with other organizations that are not directly involved in this process. If you have further questions or concerns, you may contact us at: 972.772.4104
All rights reserved. No part of this publication may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical, photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.
© 2008 by Creative Cancer Concepts, Inc. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.
|
All correspondence should be directed to:
Editor, Ten Things You Need to Know About Vesicant Extravasations
Creative Cancer Concepts, Inc.
705 N. Goliad St.
Rockwall, TX 75087
Phone: 972.772.4104
Fax: 972.722.8323
Email: c3administrator@creativecancerconcepts.com
I have read the above and wish to participate in this online education activity.
|
|
| |
|
|
